Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700527 · ClinicalTrials.gov registry record · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
A Phase 1 study of Radiation Toxicity and Toxicity, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT04700527 is a Phase 1 study of Radiation Toxicity and Toxicity that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 122 participants, below the 463-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04700527, a Phase 1 study of Radiation Toxicity and Toxicity, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
Conditions Studied
Interventions
- DRUG Short Chain Fatty Acid
- DRUG Tapioca Flour
Study Locations (1)
North Carolina
- Flora Danquah - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700527
The ClinicalTrials.gov registry entry for NCT04700527 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (74% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Radiation Toxicity appearing as the primary indexed condition, and to 2 interventions - of which Short Chain Fatty Acid is the first listed.
NCT04700527 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04700527 about?
NCT04700527 is a clinical study titled "The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study". The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
What is the current status of trial NCT04700527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2023-12-15. Estimated completion is 2030-05.
What conditions does trial NCT04700527 study?
This clinical trial studies the following conditions: Radiation Toxicity, Toxicity.
What interventions are being tested in trial NCT04700527?
The interventions under investigation include: Short Chain Fatty Acid (DRUG), Tapioca Flour (DRUG).
Who is sponsoring clinical trial NCT04700527?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700527 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
COMPLETED · Phase 1
-
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
COMPLETED · Phase 1
-
Monoclonal Antibody Therapy in Treating Patients With Leukemia
COMPLETED · Phase 1
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.